These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 30575329)
41. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722 [TBL] [Abstract][Full Text] [Related]
42. Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. Goldsbury DE; Weber MF; Yap S; Rankin NM; Ngo P; Veerman L; Banks E; Canfell K; O'Connell DL PLoS One; 2020; 15(8):e0238018. PubMed ID: 32866213 [TBL] [Abstract][Full Text] [Related]
43. Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter? Chen AB; Li L; Cronin AM; Brooks GA; Kavanagh BD; Schrag D Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):3227-3244. PubMed ID: 28858372 [TBL] [Abstract][Full Text] [Related]
44. Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Steuten L; Garmo V; Phatak H; Sullivan SD; Nghiem P; Ramsey SD Appl Health Econ Health Policy; 2019 Oct; 17(5):733-740. PubMed ID: 31250217 [TBL] [Abstract][Full Text] [Related]
45. Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis. Lokhandwala T; Bittoni MA; Dann RA; D'Souza AO; Johnson M; Nagy RJ; Lanman RB; Merritt RE; Carbone DP Clin Lung Cancer; 2017 Jan; 18(1):e27-e34. PubMed ID: 27530054 [TBL] [Abstract][Full Text] [Related]
46. Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. Hassett MJ; Banegas M; Uno H; Weng S; Cronin AM; O'Keeffe Rosetti M; Carroll NM; Hornbrook MC; Ritzwoller DP J Oncol Pract; 2019 Jul; 15(7):e616-e627. PubMed ID: 31107629 [TBL] [Abstract][Full Text] [Related]
47. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223 [TBL] [Abstract][Full Text] [Related]
48. Attributable costs of differentiated thyroid cancer in the elderly Medicare population. Boltz MM; Hollenbeak CS; Schaefer E; Goldenberg D; Saunders BD Surgery; 2013 Dec; 154(6):1363-9; discussion 1369-70. PubMed ID: 23973115 [TBL] [Abstract][Full Text] [Related]
49. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Shen C; Dasari A; Gu D; Chu Y; Zhou S; Xu Y; Halperin D; Fu S; Yao JC; Shih YT Pharmacoeconomics; 2018 Aug; 36(8):1005-1013. PubMed ID: 29682693 [TBL] [Abstract][Full Text] [Related]
50. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Etzioni R; Ramsey SD; Berry K; Brown M Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190 [TBL] [Abstract][Full Text] [Related]
51. The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience. Zeng X; Karnon J; Wang S; Wu B; Wan X; Peng L PLoS One; 2012; 7(10):e48323. PubMed ID: 23118985 [TBL] [Abstract][Full Text] [Related]
52. Area-level variations in cancer care and outcomes. Keating NL; Landrum MB; Lamont EB; Bozeman SR; McNeil BJ Med Care; 2012 May; 50(5):366-73. PubMed ID: 22437623 [TBL] [Abstract][Full Text] [Related]
53. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Stokes ME; Black L; Benedict A; Roehrborn CG; Albertsen P Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521 [TBL] [Abstract][Full Text] [Related]
54. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793 [TBL] [Abstract][Full Text] [Related]
55. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Evans WK; Will BP; Berthelot JM; Wolfson MC Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457 [TBL] [Abstract][Full Text] [Related]
56. Cost disparities in lung cancer treatment by disability status, sex, and race. Chirikos TN; Roetzheim RG; McCarthy EP; Iezzoni LI Disabil Health J; 2008 Apr; 1(2):108-15. PubMed ID: 19881893 [TBL] [Abstract][Full Text] [Related]
57. The Cost to Medicare of Bladder Cancer Care. Sloan FA; Yashkin AP; Akushevich I; Inman BA Eur Urol Oncol; 2020 Aug; 3(4):515-522. PubMed ID: 31412015 [TBL] [Abstract][Full Text] [Related]
58. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data. Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494 [TBL] [Abstract][Full Text] [Related]
59. The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis. Raab SS; Hornberger J; Raffin T Chest; 1997 Oct; 112(4):937-45. PubMed ID: 9377956 [TBL] [Abstract][Full Text] [Related]
60. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics. Rein DB; Borton J; Liffmann DK; Wittenborn JS Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]